Cytochrome P450-derived epoxyeicosatrienoic acids and coronary artery disease in humans: A targeted metabolomics study

Journal of Lipid Research

Volumn 57, Issue 1, 2016, Pages 109-119

  Oni Orisan, Akinyemi ^a,b   Edin, Matthew L ^c   Lee, John Andrew ^a   Wells, Michael A ^a   Christensen, Erin S ^a   Vendrov, Kimberly C ^a   Lih, Fred B ^c   Tomer, Kenneth B ^c   Bai, Xue ^d   Taylor, Joan M ^d   Stouffer, George A ^d   Zeldin, Darryl C ^c   Lee, Craig R ^a,b,d  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b UNC Hamner Institute for Drug Safety Sciences   (United States)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Arachidonic acid; AthErosclerosis; Eicosanoids; Heart; Inflammation; Pharmacometabolomics; Precision medicine

Indexed keywords

11,12 DIHYDROXYEICOSATRIENOIC ACID; 11,12 EPOXYEICOSATRIENOIC ACID; 14,15 DIHYDROXYEICOSATRIENOIC ACID; 14,15 EPOXY 5,8,11 ICOSATRIENOIC ACID; 5,6 DIHYDROXYEICOSATRIENOIC ACID; 8,9 DIHYDROXYEICOSATRIENOIC ACID; 8,9 EPOXYEICOSATRIENOIC ACID; BIOLOGICAL MARKER; CYTOCHROME P450; EPOXYICOSATRIENOIC ACID; ICOSANOID; LIPOXYGENASE; PROSTAGLANDIN SYNTHASE; UNCLASSIFIED DRUG; ARACHIDONIC ACID; ARACHIDONIC ACID DERIVATIVE; DIHOMO GAMMA LINOLENIC ACID; HYDROXYICOSATETRAENOIC ACID;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DISEASE ASSOCIATION; FATTY ACID SYNTHESIS; FEMALE; FOLLOW UP; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; BLOOD; CORONARY ANGIOGRAPHY; INFLAMMATION; METABOLISM; MIDDLE AGED;

8,11,14-EICOSATRIENOIC ACID; ADULT; AGED; ARACHIDONIC ACID; ARACHIDONIC ACIDS; BIOMARKERS; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; HYDROXYEICOSATETRAENOIC ACIDS; INFLAMMATION; MALE; METABOLOMICS; MIDDLE AGED;

EID: 84956789017     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M061697     Document Type: Article

References (51)

1. Mozaffarian, D., E. J. Benjamin, A. S. Go, D. K. Arnett, M. J. Blaha, M. Cushman, S. de Ferranti, J. P. Després, H. J. Fullerton, V. J. Howard, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. 2015. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation. 131: e29-e322.
2. Waldman, S. A., and A. Terzic. 2014. Molecular insights provide the critical path to disease mitigation. Clin. Pharmacol. Ther. 95: 3-7.
3. Bernhardt, R. 2006. Cytochromes P450 as versatile biocatalysts. J. Biotechnol. 124: 128-145.
4. Zeldin, D. C. 2001. Epoxygenase pathways of arachidonic acid metabolism. J. Biol. Chem. 276: 36059-36062.
5. Deng, Y., K. N. Theken, and C. R. Lee. 2010. Cytochrome P450 epoxygenases, soluble epoxide hydrolase, and the regulation of cardiovascular inflammation. J. Mol. Cell. Cardiol. 48: 331-341.
6. Imig, J. D. 2012. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol. Rev. 92: 101-130.
7. Oni-Orisan, A., N. Alsaleh, C. R. Lee, and J. M. Seubert. 2014. Epoxyeicosatrienoic acids and cardioprotection: the road to translation. J. Mol. Cell. Cardiol. 74: 199-208.
8. Spiecker, M., H. Darius, T. Hankeln, M. Soufi, A. M. Sattler, J. R. Schaefer, K. Node, J. Borgel, A. Mugge, K. Lindpaintner, et al. 2004. Risk of coronary artery disease associated with polymorphism of the cytochrome P450 epoxygenase CYP2J2. Circulation. 110: 2132-2136.
9. Lee, C. R., K. E. North, M. S. Bray, D. J. Couper, G. Heiss, and D. C. Zeldin. 2007. CYP2J2 and CYP2C8 polymorphisms and coronary heart disease risk: the Atherosclerosis Risk in Communities (ARIC) study. Pharmacogenet. Genomics. 17: 349-358.
10. Lee, C. R., K. E. North, M. S. Bray, M. Fornage, J. M. Seubert, J. W. Newman, B. D. Hammock, D. J. Couper, G. Heiss, and D. C. Zeldin. 2006. Genetic variation in soluble epoxide hydrolase (EPHX2) and risk of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Hum. Mol. Genet. 15: 1640-1649.
11. Köfeler, H. C., A. Fauland, G. N. Rechberger, and M. Trötzmüller. 2012. Mass spectrometry based lipidomics: an overview of technological platforms. Metabolites. 2: 19-38.
12. Levine, G. N., E. R. Bates, J. C. Blankenship, S. R. Bailey, J. A. Bittl, B. Cercek, C. E. Chambers, S. G. Ellis, R. A. Guyton, S. M. Hollenberg, et al.; American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidelines, and Society for Cardiovascular Angiography and Interventions. 2013. 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Catheter. Cardiovasc. Interv. 82: E266-E355.
13. Zha, W., M. L. Edin, K. C. Vendrov, R. N. Schuck, F. B. Lih, J. L. Jat, J. A. Bradbury, L. M. DeGraff, K. Hua, K. B. Tomer, et al. 2014. Functional characterization of cytochrome P450-derived epoxyeicosatrienoic acids in adipogenesis and obesity. J. Lipid Res. 55: 2124-2136.
14. Edin, M. L., Z. Wang, J. A. Bradbury, J. P. Graves, F. B. Lih, L. M. DeGraff, J. F. Foley, R. Torphy, O. K. Ronnekleiv, K. B. Tomer, et al. 2011. Endothelial expression of human cytochrome P450 epoxygenase CYP2C8 increases susceptibility to ischemiareperfusion injury in isolated mouse heart. FASEB J. 25: 3436-3447.
15. Newman, J. W., T. Watanabe, and B. D. Hammock. 2002. The simultaneous quantifi cation of cytochrome P450 dependent linoleate and arachidonate metabolites in urine by HPLC-MS/MS. J. Lipid Res. 43: 1563-1578.
16. Lim, C. W., K. Y. Lai, J. F. Yeo, S. H. Tai, and S. H. Chan. 2015. Quantitative assessment of moniliformin in cereals via alternative precipitation pathways, aided by LC-LIT-MS and LC-Q-TOF-MS. Food Chem. 174: 372-379.
17. Theken, K. N., Y. Deng, M. A. Kannon, T. M. Miller, S. M. Poloyac, and C. R. Lee. 2011. Activation of the acute inflammatory response alters cytochrome P450 expression and eicosanoid metabolism. Drug Metab. Dispos. 39: 22-29.
18. Schuck, R. N., K. N. Theken, M. L. Edin, M. Caughey, A. Bass, K. Ellis, B. Tran, S. Steele, B. P. Simmons, F. B. Lih, et al. 2013. Cytochrome P450-derived eicosanoids and vascular dysfunction in coronary artery disease patients. Atherosclerosis. 227: 442-448.
19. Xia, J., R. Mandal, I. V. Sinelnikov, D. Broadhurst, and D. S. Wishart. 2012. MetaboAnalyst 2.0 - a comprehensive server for metabolomic data analysis. Nucleic Acids Res. 40: W127-W133.
20. Maddox, T. M., M. A. Stanislawski, G. K. Grunwald, S. M. Bradley, P. M. Ho, T. T. Tsai, M. R. Patel, A. Sandhu, J. Valle, D. J. Magid, et al. 2014. Nonobstructive coronary artery disease and risk of myocardial infarction. J. Am. Med. Assoc. 312: 1754-1763.
21. Koerselman, J., Y. van der Graaf, P. P. de Jaegere, and D. E. Grobbee. 2003. Coronary collaterals: an important and underexposed aspect of coronary artery disease. Circulation. 107: 2507-2511.
22. Roman, R. J. 2002. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol. Rev. 82: 131-185.
23. Campbell, W. B., D. Gebremedhin, P. F. Pratt, and D. R. Harder. 1996. Identifi cation of epoxyeicosatrienoic acids as endotheliumderived hyperpolarizing factors. Circ. Res. 78: 415-423.
24. Node, K., Y. Huo, X. Ruan, B. Yang, M. Spiecker, K. Ley, D. C. Zeldin, and J. K. Liao. 1999. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 285: 1276-1279.
25. Dhanasekaran, A., S. K. Gruenloh, J. N. Buonaccorsi, R. Zhang, G. J. Gross, J. R. Falck, P. K. Patel, E. R. Jacobs, and M. Medhora. 2008. Multiple antiapoptotic targets of the PI3K/Akt survival pathway are activated by epoxyeicosatrienoic acids to protect cardiomyocytes from hypoxia/anoxia. Am. J. Physiol. Heart Circ. Physiol. 294: H724-H735.
26. Imig, J. D., and B. D. Hammock. 2009. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug Discov. 8: 794-805.
27. Morgan, E. T. 2001. Regulation of cytochrome p450 by inflammatory mediators: why and how? Drug Metab. Dispos. 29: 207-212.
28. Hansson, G. K. 2005. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352: 1685-1695.
29. Schuck, R. N., W. Zha, M. L. Edin, A. Gruzdev, K. C. Vendrov, T. M. Miller, Z. Xu, F. B. Lih, L. M. DeGraff, K. B. Tomer, et al. 2014. The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One. 9: e110162.
30. Kessler, P., R. Popp, R. Busse, and V. B. Schini-Kerth. 1999. Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation. 99: 1878-1884.
31. Powell, P. K., I. Wolf, R. Jin, and J. M. Lasker. 1998. Metabolism of arachidonic acid to 20-hydroxy-5,8,11,14-eicosatetraenoic acid by P450 enzymes in human liver: involvement of CYP4F2 and CYP4A11. J. Pharmacol. Exp. Ther. 285: 1327-1336.
32. Qu, W., J. A. Bradbury, C. C. Tsao, R. Maronpot, G. J. Harry, C. E. Parker, L. S. Davis, M. D. Breyer, M. P. Waalkes, J. R. Falck, et al. 2001. Cytochrome P450 CYP2J9, a new mouse arachidonic acid omega-1 hydroxylase predominantly expressed in brain. J. Biol. Chem. 276: 25467-25479.
33. Wu, S., W. Chen, E. Murphy, S. Gabel, K. B. Tomer, J. Foley, C. Steenbergen, J. R. Falck, C. R. Moomaw, and D. C. Zeldin. 1997. Molecular cloning, expression, and functional signifi cance of a cytochrome P450 highly expressed in rat heart myocytes. J. Biol. Chem. 272: 12551-12559.
34. Spector, A. A., X. Fang, G. D. Snyder, and N. L. Weintraub. 2004. Epoxyeicosatrienoic acids (EETs): metabolism and biochemical function. Prog. Lipid Res. 43: 55-90.
35. Shearer, G. C., and J. W. Newman. 2009. Impact of circulating esterifi ed eicosanoids and other oxylipins on endothelial function. Curr. Atheroscler. Rep. 11: 403-410.
36. Shearer, G. C., and J. W. Newman. 2008. Lipoprotein lipase releases esterifi ed oxylipins from very low-density lipoproteins. Prostaglandins Leukot. Essent. Fatty Acids. 79: 215-222.
37. Newman, J. W., T. L. Pedersen, V. R. Brandenburg, W. S. Harris, and G. C. Shearer. 2014. Effect of omega-3 fatty acid ethyl esters on the oxylipin composition of lipoproteins in hypertriglyceridemic, statin-treated subjects. PLoS One. 9: e111471.
38. Ramirez, C. E., M. M. Shuey, G. L. Milne, K. Gilbert, N. Hui, C. Yu, J. M. Luther, and N. J. Brown. 2014. Arg287Gln variant of EPHX2 and epoxyeicosatrienoic acids are associated with insulin sensitivity in humans. Prostaglandins Other Lipid Mediat. 113-115: 38-44.
39. Minuz, P., H. Jiang, C. Fava, L. Turolo, S. Tacconelli, M. Ricci, P. Patrignani, A. Morganti, A. Lechi, and J. C. McGiff. 2008. Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. Hypertension. 51: 1379-1385.
40. Theken, K. N., R. N. Schuck, M. L. Edin, B. Tran, K. Ellis, A. Bass, F. B. Lih, K. B. Tomer, S. M. Poloyac, M. C. Wu, et al. 2012. Evaluation of cytochrome P450-derived eicosanoids in humans with stable atherosclerotic cardiovascular disease. Atherosclerosis. 222: 530-536.
41. Planagumà, A., M. A. Pfeffer, G. Rubin, R. Croze, M. Uddin, C. N. Serhan, and B. D. Levy. 2010. Lovastatin decreases acute mucosal inflammation via 15-epi-lipoxin A4. Mucosal Immunol. 3: 270-279.
42. Fisslthaler, B., U. R. Michaelis, V. Randriamboavonjy, R. Busse, and I. Fleming. 2003. Cytochrome P450 epoxygenases and vascular tone: novel role for HMG-CoA reductase inhibitors in the regulation of CYP 2C expression. Biochim. Biophys. Acta. 1619: 332-339.
43. de Lemos, J. A., D. A. Morrow, M. A. Blazing, P. Jarolim, S. D. Wiviott, M. S. Sabatine, R. M. Califf, and E. Braunwald. 2007. Serial measurement of monocyte chemoattractant protein-1 after acute coronary syndromes: results from the A to Z trial. J. Am. Coll. Cardiol. 50: 2117-2124.
44. Tsikas, D., and A. A. Zoerner. 2014. Analysis of eicosanoids by LC-MS/MS and GC-MS/MS: a historical retrospect and a discussion. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 964: 79-88.
45. Pammolli, F., L. Magazzini, and M. Riccaboni. 2011. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10: 428-438.
46. Pacanowski, M. A., C. Leptak, and I. Zineh. 2014. Next-generation medicines: past regulatory experience and considerations for the future. Clin. Pharmacol. Ther. 95: 247-249.
47. Shen, H. C., and B. D. Hammock. 2012. Discovery of inhibitors of soluble epoxide hydrolase: a target with multiple potential therapeutic indications. J. Med. Chem. 55: 1789-1808.
48. Falck, J. R., S. R. Koduru, S. Mohapatra, R. Manne, R. Atcha, V. L. Manthati, J. H. Capdevila, S. Christian, J. D. Imig, and W. B. Campbell. 2014. 14,15-Epoxyeicosa-5,8,11-trienoic acid (14,15-EET) surrogates: carboxylate modifi cations. J. Med. Chem. 57: 6965-6972
49. [Erratum. 2014. J. Med. Chem. 57: 9218.]
50. Podolin, P. L., B. J. Bolognese, J. F. Foley, E. Long III, B. Peck, S. Umbrecht, X. Zhang, P. Zhu, B. Schwartz, W. Xie, et al. 2013. In vitro and in vivo characterization of a novel soluble epoxide hydrolase inhibitor. Prostaglandins Other Lipid Mediat. 104-105: 25-31.
51. Zhu, P., B. Peck, H. Licea-Perez, J. F. Callahan, and C. Booth-Genthe. 2011. Development of a semi-automated LC/MS/MS method for the simultaneous quantitation of 14,15-epoxyeicosatrienoic acid, 14,15-dihydroxyeicosatrienoic acid, leukotoxin and leukotoxin diol in human plasma as biomarkers of soluble epoxide hydrolase activity in vivo. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 879: 2487-2493.